Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
MiNK Therapeutics Announces Clinical Data of Allogeneic
Allogeneic iNKTs, agenT-797, administered alone or in combination…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Allogeneic
Cellectis Provides Business Update and Reports Fourth
<!-- Name:DistributionId Value:8784587 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial
<!-- Name:DistributionId Value:8782306 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal…
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (p<0.001)
No New Safety Signals Were Seen with…
- Advertisement -
GAIA BioMedicine and TreeFrog Therapeutics Announce
<!-- Name:DistributionId Value:1000782840 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Cellectis Announces Closing of Global Offering and Exercise
<!-- Name:DistributionId Value:8744861 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Cellectis Supplements the Announcement of the Pricing of
<!-- Name:DistributionId Value:8742522 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Cellectis Announces Pricing of Follow-On Offering
<!-- Name:DistributionId Value:8742244 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
- Advertisement -
Cellectis Amends $20 Million Convertible Note Under
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene…
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies, today announced the appointment of…